×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Should You Buy Axsome Therapeutics (AXSM) Ahead of Earnings?
Zacks Investment Research
Axsome Therapeutics (AXSM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into...
1 day ago
Axsome Therapeutics Recognizes May as Mental Health Awareness Month
GlobeNewswire
NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering...
3 days ago
Axsome Therapeutics recognizes May as Mental Health Awareness Month - TipRanks.com
Tipranks
Axsome Therapeutics is joining the global community of mental health advocates, including Mental Health America, during May's Mental Health...
3 days ago
Morgan Stanley upgrades Axsome stock, bullish on Alzheimer's and depression drug prospects
Investing.com
On Monday, Morgan Stanley adjusted its stance on Axsome Therapeutics (NASDAQ:AXSM) stock, elevating from Equalweight to Overweight and...
5 days ago
Axsome Therapeutics stock rises on upgrade to Overweight at Morgan Stanley (NASDAQ:AXSM)
Seeking Alpha
Axsome Therapeutics (NASDAQ:AXSM) has been upgraded to Overweight from Equal-weight by Morgan Stanley banking on positive expected results...
5 days ago
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
Yahoo Finance
NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering...
3 weeks ago
Peeling Back The Layers: Exploring Axsome Therapeutics Through Analyst Insights - Axsome Therapeutics (NASDAQ ...
Benzinga
Providing a diverse range of perspectives from bullish to bearish, 18 analysts have published ratings on Axsome Therapeutics.
5 days ago
AAN 2024: new pooled data highlights efficacy of Axsome Therapeutics's AXS-07
Clinical Trials Arena
At AAN 2024, Axsome Therapeutics presented new pooled data from two Phase III trials evaluating AXS-07 as an acute treatment for migraine in...
2 weeks ago
AXSM Stock Tumbles On An Unexpected Setback For Axsome's Alzheimer's Drug
Investor's Business Daily
Axsome Tumbles On An Unexpected Setback For Its Alzheimer's Drug ... Axsome Therapeutics (AXSM) reported strong fourth-quarter sales Tuesday, but...
2 months ago
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term ...
GlobeNewswire
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm,...
3 days ago